Scholars@Duke
Adam Silverstein

Adam Silverstein

Biostatistician, Principal
Duke Clinical Research Institute
adam.silverstein@duke.edu
300 West Morgan Street, 4th Floor - Statistics, Durham, NC 27701
300 West Morgan Street, 4th Floor - Statistics, Durham, NC 27705

Scholarly Works

Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.

Journal article JAMA Neurol · January 1, 2026 IMPORTANCE: Treatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need. OBJECTIVE: To te ... Full text Link to item Cite

RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC).

Journal article Trials · May 17, 2024 BACKGROUND: Post-acute sequelae of SARS-CoV-2 infection (PASC) symptoms have broad impact, and may affect individuals regardless of COVID-19 severity, socioeconomic status, race, ethnicity, or age. A prominent PASC symptom is cognitive dysfunction, colloqu ... Full text Open Access Link to item Cite

Prognostic Impact of Sinus Rhythm in Atrial Fibrillation Patients: Separating Rhythm Outcomes From Randomized Strategy Findings From the CABANA Trial.

Journal article Circ Arrhythm Electrophysiol · May 2024 BACKGROUND: Clinically detected atrial fibrillation (AF) is associated with a significant increase in mortality and other adverse cardiovascular events. Since the advent of effective methods for AF rhythm control, investigators have attempted to determine ... Full text Open Access Link to item Cite

Regional differences in outcomes with ablation versus drug therapy for atrial fibrillation: Results from the CABANA trial.

Journal article Am Heart J · April 2024 BACKGROUND: The finding of unexpected variations in treatment benefits by geographic region in international clinical trials raises complex questions about the interpretation and generalizability of trial findings. We observed such geographical variations ... Full text Open Access Link to item Cite

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

Journal article JAMA · July 25, 2023 IMPORTANCE: Immune dysregulation contributes to poorer outcomes in COVID-19. OBJECTIVE: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS: Ra ... Full text Open Access Link to item Cite

Effects of Ablation Versus Drug Therapy on Quality of Life by Sex in Atrial Fibrillation: Results From the CABANA Trial.

Journal article J Am Heart Assoc · February 7, 2023 Background Women with atrial fibrillation (AF) demonstrate more AF-related symptoms and worse quality of life (QOL). Whether increased use of ablation in women reduces sex-related QOL differences is unknown. Sex-related outcomes for ablation versus drug th ... Full text Open Access Link to item Cite

Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA.

Journal article Europace · October 13, 2022 AIMS: Influence of atrial fibrillation (AF) type on outcomes seen with catheter ablation vs. drug therapy is incompletely understood. This study assesses the impact of AF type on treatment outcomes in the Catheter Ablation vs. Antiarrhythmic Drug Therapy f ... Full text Open Access Link to item Cite

Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.

Journal article Pediatr Infect Dis J · July 1, 2022 BACKGROUND: Solithromycin is a new macrolide-ketolide antibiotic with potential effectiveness in pediatric community-acquired bacterial pneumonia (CABP). Our objective was to evaluate its safety and effectiveness in children with CABP. METHODS: This phase ... Full text Open Access Link to item Cite

Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.

Journal article Circulation · March 15, 2022 BACKGROUND: Observational data suggest that catheter ablation may be safe and effective to treat younger and older patients with atrial fibrillation. No large, randomized trial has examined this issue. This report describes outcomes according to age at ent ... Full text Open Access Link to item Cite

Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.

Journal article J Am Coll Cardiol · July 13, 2021 BACKGROUND: Rhythm control strategies for atrial fibrillation (AF), including catheter ablation, are substantially underused in racial/ethnic minorities in North America. OBJECTIVES: This study sought to describe outcomes in the CABANA trial as a function ... Full text Open Access Link to item Cite

Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial.

Journal article Circulation · April 6, 2021 BACKGROUND: In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatm ... Full text Open Access Link to item Cite

Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results From the CABANA Trial.

Journal article Circulation · February 16, 2021 BACKGROUND: Among patients with atrial fibrillation (AF), women are less likely to receive catheter ablation and may have more complications and less durable results. Most information about sex-specific differences after ablation comes from observational d ... Full text Open Access Link to item Cite

Geographical region differences in the Cabana trials

Conference EUROPEAN HEART JOURNAL · November 2020 Link to item Cite

Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial.

Journal article J Am Coll Cardiol · June 30, 2020 BACKGROUND: The CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 patients with atrial fibrillation (AF) to catheter ablation or drug therapy. Analysis by intention-to-treat showed a nonsignificant ... Full text Open Access Link to item Cite

Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Journal article JAMA · April 2, 2019 IMPORTANCE: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain. OBJECTIVE: To determine whether catheter ablation is more effective than conventional me ... Full text Open Access Link to item Cite

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Journal article Am Heart J · February 2019 BACKGROUND: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with ... Full text Open Access Link to item Cite

Neurological complications of anticoagulation therapy: a neurologist's review.

Journal article Archives of internal medicine · February 1979 Anticoagulant-induced bleeding may involve the brain, spinal cord, or peripheral nerves. It may occur with either coumarin or heparin anticoagulants, in the absence of trauma, and while prothrombin times, clotting times, or partial thromboplastin times are ... Full text Cite

Primary pontile hemorrhage. A review of 50 cases.

Journal article Confinia neurologica · January 1967 Full text Cite

NEUROPATHY IN HEMOPHILIA.

Journal article JAMA · November 1964 Full text Cite